CClinicalTrials.gg
Active, not recruitingNCT05885906Updated Sep 14, 2023

Aloe Vera Versus Thyme Honey Mouthwash in Management of Xerostomia in Type 2 Diabetics

A Phase 3 interventional study of Aloevera and Thyme honey in Xerostomia, sponsored by Ain Shams University. Active, not recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Ain Shams University · Phase 3, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as active, not recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Sex
All
01

Study summary

The objectives of the present study are to:

  1. Compare the clinical efficacy of (50%) aloe vera versus (20%) thyme honey mouthwash on management of xerostomia in diabetic patients by measuring the salivary flow rate as a primary objective.
  2. Asses the biochemical effect of aloe vera and thyme honey on the level of salivary nitric oxide, xerostomia grade as well as patient quality of life as a secondary objective.

Research question:

Which is better aloe vera or thyme honey in improving salivary flow rate in diabetic patients suffering from xerostomia?

Patient Grouping and Randomization:

Patients with xerostomia will be randomly distributed into three groups using a computer-generated randomization table. Allocation concealment will be achieved by a sealed opaque envelope with a ratio of 1:1:1

Group 1 (Aloe Vera group)

Include (15) patient suffering from diabetes induced xerostomia that will receive aloe vera as mouthwash

Group 2 (Thyme honey group):

Include (15) patient suffering from diabetes induced xerostomia that will receive thyme honey mouthwash

Group 3 (Saline control group):

Include (15) patient suffering from diabetes induced xerostomia that will receive saline mouthwash

Read the detailed description

Saliva is a complex mix from major as well as minor salivary glands and gingival crevicular fluids. It is a clear and slightly acidic diluted secretion with more than 99% water, electrolytes, immunoglobulins, enzymes, proteins, mucin and nitrogenous products. Subjective feeling of a dry mouth is known as xerostomia, which may result from diminished saliva production, but some people reported feeling a dry mouth even though there was no decrease in saliva quantity.Diabetes mellitus is considered one of the main causes of xerostomia There are different treatments modalities of xerostomia which include pharmacological and non-pharmacological treatments.Recently different herbs were used in the treatment of xerostomia and showed promising results and great patient acceptance among which aloe vera and thyme honey are used.

02

Conditions studied

  • Xerostomia

Browse trials for

Keywords

  • Xerostomia
  • Aloevera
  • Thyme honey
  • type 2 diabetes
03

In context

Xerostomia

254 studies on the registry are indexed under Xerostomia; 47 are open to participants now.

This study's planned enrollment of 45 is close to the median of 42 across 216 interventional studies indexed under Xerostomia.

Browse Xerostomia studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Both gender, with type 2 diabetes mellitus only and suffering from xerostomia.
  2. Patients willing to follow all the instructions and attend all the study-associated visits.

Exclusion criteria

Exclusion Criteria:

  1. Patients who had received radiation therapy to the head and neck region.
  2. Patients with other systemic diseases known to cause xerostomia (Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, hepatitis C virus, tuberculosis, or sarcoidosis).
  3. Patients using any other medication for their dry mouth condition (pilocarpine, cevimeline) 7 days before entering into the study.
  4. Patients requiring hospitalization for any medical problem during the study.
  5. Known hypersensitivity to the active ingredient of the product that will be used as assessed by the medical history questionnaire.
  6. Vulnerable groups such as mentally or physically handicapped individuals, pregnant females, prisoners.
05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Aloevera group

    15 patients suffering from diabetes induced xerostomia that will receive aloe vera as mouthwash (20 ml of aloe vera 50%) 3 times per day for 4 weeks.

    Drug: Aloevera

  • Active comparator
    Thyme honey group

    15 patients suffering from diabetes induced xerostomia that will receive thyme honey mouthwash (20 ml of thyme honey diluted in 100 ml of distilled water) 3 times per day for 4 weeks.

    Drug: Thyme honey

  • Placebo comparator
    Saline group

    15 patients suffering from diabetes induced xerostomia that will receive saline mouthwash as a control group (20 ml of saline) 3 times per day for 4 weeks.

    Drug: Saline

Interventions

  • DrugAloevera

    Mouthwash

  • DrugThyme honey

    Mouthwash

  • DrugSaline

    Mouthwash

06

What researchers measure

Primary outcomes

  1. Change in unstimulated Salivary flow rate

    Milliliters

    Time frame: Baseline, 2weeks and 4weeks

07

Study locations

1 site
  • Faculty of dentistry Ain shams university
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05885906
Lead sponsor
Ain Shams University
Responsible party
Dina Borham Abdelhafez Abdellatif Elkhouly (Resident, Ain Shams University) — Principal investigator
First posted
Jun 2, 2023
Start date
Jul 24, 2023
Primary completion
Oct 2023 (estimated)
Completion
Mar 2024 (estimated)
Last update
Sep 14, 2023

Study contacts

Radwa Rageb, PHD
study director · Ain Shams University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion